Clinical trials: Cancer Patients and Physical Activity
Diffuse Large B Cell Lymphoma (DLBCL)
A Study of HDM2005 in Combination With Standard of Care in Patients With Diffuse Large B-Cell Lymphoma
The purpose of this phase 1b/2 study is to evaluate the safety, tolerability, and antitumor activity of HDM2005 in combination with standard of care in participants with diffuse large B-cell lymphoma.
- Trial name
- NCT07124936
- Testing
- HDM2005, Rituximab or Rituximab biosimilar, Gemcitabine
- Where
- 21 sites in China
- Volunteers
- 97 people
- Sponsor
- Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Advanced Solid Tumor, Metastatic Solid Tumor
A Study of GI-108, an Anti-CD73-IgG4 Fc-IL-2v Bispecific Fusion Protein, as Monotherapy in Patients With Advanced or Metastatic Solid Tumors
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and therapeutic activity of GI-108, as a single agent, in patients with advanced or metastatic solid tumors
- Conditions
- Advanced Solid Tumor, Metastatic Solid Tumor, Non-small Cell Lung Cancer (NSCLC), Head and Neck (HNSCC)
- Trial name
- NCT07172802
- Testing
- GI-108
- Where
- 3 sites in South Korea
- Volunteers
- 102 people
- Sponsor
- GI Innovation, Inc.
ER+ HER2- Advanced Breast Cancer
AZD9496 First Time in Patients Ascending Dose Study
This is a phase 1 open label multicentre study of AZD9496 administered orally in patients with advanced ER+ HER2 negative breast cancer.
- Trial name
- NCT02248090
- Testing
- AZD9496
- Where
- 6 sites in United States, South Korea and 1 more
- Volunteers
- 45 people
- Sponsor
- AstraZeneca
Multiple Myeloma
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of XmAb24306 in Combination With Cevostamab in Participants With Relapsed/Refractory Multiple Myeloma
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and activity of XmAb24306 in combination with cevostamab in participants with relapsed/refractory multiple myeloma (R/R MM) who have received a…
- Trial name
- NCT05646836
- Testing
- Cevostamab, XmAb24306, Tocilizumab
- Where
- 13 sites in Australia, Denmark and 5 more
- Volunteers
- 90 people
- Sponsor
- Genentech, Inc.
Neoplasms, Neoplasm Metastasis
A Study of LY3022855 In Participants With Breast or Prostate Cancer
The main purpose of this study is to learn more about how the investigational drug, LY3022855, affects the immune system in participants with advanced breast or prostate cancer that has not responded to other treatments.
- Trial name
- NCT02265536
- Testing
- LY3022855
- Where
- 2 sites in United States
- Volunteers
- 34 people
- Sponsor
- Eli Lilly and Company
Chronic Lymphocytic Leukemia (CLL)
Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL)
Chronic lymphocytic leukemia (CLL) is the most common leukemia (cancer of blood cells). The purpose of this study is to assess retreatment with venetoclax-obinutuzumab (VenG) in participants previously treated with fixed duration…
- Trial name
- ReVenG (NCT04895436)
- Testing
- Venetoclax, Obinutuzumab
- Where
- 58 sites in United States, Australia and 9 more
- Volunteers
- 75 people
- Sponsor
- AbbVie
Metastatic Solid Tumors, Locally Advanced Solid Tumors
This Study is to Evaluate Safe and Effective Treatment Dose of OBI-888 in Patients With Locally Advanced or Metastatic Solid Tumors.
The purpose of this study is to establish the maximum tolerated dose (MTD) of OBI-888 as monotherapy. And to characterize the safety and preliminary clinical activity profile of the MTD dose of OBI-888 administered as monotherapy…
- Trial name
- NCT03573544
- Testing
- OBI-888, Globo H IHC Assay
- Where
- 9 sites in United States, Taiwan
- Volunteers
- 54 people
- Sponsor
- OBI Pharma, Inc
Advance Solid Tumors, Lymphoma, Non-Hodgkin
Study of JMBI-001 in Patients With MYC-Positive Advanced Cancers
Evaluate the safety and tolerability of JMBI-001 in adults with MYC-positive advanced cancers.
- Trial name
- PANGU-1 (NCT07864701)
- Testing
- JMBI-001 Tablets
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Chengdu Anticancer Bioscience, Ltd.
Lymphoma, Non-Hodgkin
A Phase I, Dose-Escalation Study to Assess the Safety and Biological Activity of Recombinant Human Interleukin-18
The purpose is to identify a dose of SB-485232 which is safe, tolerable and effective when used in combination with Rituximab in patients with non-Hodgkin's lymphoma (NHL).
- Trial name
- NCT00500058
- Testing
- SB-485232, Rituximab
- Where
- 2 sites in United States
- Volunteers
- 24 people
- Sponsor
- GlaxoSmithKline
Advanced Solid Tumor
A Phase I Study to Evaluate the Safety, Pharmacokinetics and Antitumor Activity of HC010 in Patients With Advanced Solid Tumors
This clinical trial is a multicenter, open, single-arm, non-randomized, dose-escalation and dose-expansion, phase I clinical study in patients with advanced recurrent or metastatic solid tumors.The goal of this study is to…
- Trial name
- NCT06307925
- Testing
- HC010
- Where
- China
- Volunteers
- 122 people
- Sponsor
- HC Biopharma Inc.
Uveal Melanoma, Choroid Neoplasm
Study Evaluating Single and Repeated Intravitreal Doses of ICON-1 in Patients With Uveal Melanoma
The purpose of this study is to evaluate the safety, tolerability, biological activity, pharmacokinetics and pharmacodynamic activity of single and repeated escalating intravitreal doses of ICON-1 in patients with primary uveal…
- Trial name
- NCT02771340
- Testing
- ICON-1
- Where
- 8 sites in United States
- Volunteers
- 10 people
- Sponsor
- Iconic Therapeutics, Inc.
Solid Tumor, NSCLC
JAB-3312 Based Combination Therapy in Adult Patients With Advanced Solid Tumors
To evaluate the safety and tolerability of JAB-3312 administered in investigational regimens in adult participants with advanced solid tumors.
- Trial name
- NCT04720976
- Testing
- JAB-3312, Binimetinib, Pembrolizumab
- Where
- 15 sites in United States
- Volunteers
- 58 people
- Sponsor
- Allist Pharmaceuticals, Inc.
Colorectal Cancer
A Trial to Evaluate the Safety and Activity of Fruquintinib in Minority Populations With Advanced, Previously Treated Colorectal Cancer
High blood pressure (hypertension) is a known side effect of the treatment with fruquintinib. Current research does not provide a clear answer whether minority groups such as Black/African American and/or Hispanic/Latino with…
- Trial name
- NCT06562543
- Testing
- Fruquintinib
- Where
- 45 sites in United States, Puerto Rico
- Volunteers
- 78 people
- Sponsor
- Takeda
Richter's Transformation
Selinexor in Initial or Refractory and/or Relapsed Richter's Transformation
This is a multi-center, phase 2, single arm, open-label study of oral selinexor monotherapy in patients with Richter's Transformation, arising in the setting of prior chronic lymphocytic leukemia (CLL), after at least one…
- Trial name
- SIRRT (NCT02138786)
- Testing
- selinexor
- Where
- 17 sites in United States, Germany and 3 more
- Volunteers
- 27 people
- Sponsor
- Karyopharm Therapeutics Inc
Tumor Lysis Syndrome
Elitek (Rasburicase) Immuno-Monitoring Study
Primary Objective: To determine the incidence, titer and type of anti-rasburicase antibodies in the context of hypersensitivity reaction(s) or the loss of uricolytic activity occurring in patients with relapsed leukemia/lymphoma…
- Trial name
- NCT01097369
- Where
- 4 sites in United States
- Volunteers
- 1 people
- Sponsor
- Sanofi
Advanced Solid Tumors
First-In-Human Study in Participants With Advanced Solid Tumors
A Phase 1 Study of KH815 for Injection to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumor Activity in Patients with Advanced Solid Tumors
- Trial name
- NCT06885645
- Testing
- KH815 for injection
- Volunteers
- 30 people
- Sponsor
- Chengdu Kanghong Biotech Co., Ltd.
Non-small Cell Lung Cancer, Head and Neck Cancer
A First-in-Human Study of JAB-3068 (SHP2 Inhibitor) in Adult Patients With Advanced Solid Tumors in China
This is a Phase 1/2a, open-label, multi-center study of JAB-3068 in Patients with advanced solid tumors.This study has two phases: dose escalation phase and dose expansion phase.
- Conditions
- Non-small Cell Lung Cancer, Head and Neck Cancer, Esophageal Cancer, Other Metastatic Solid Tumors
- Trial name
- NCT03565003
- Testing
- JAB-3068
- Where
- 4 sites in China
- Volunteers
- 126 people
- Sponsor
- Jacobio Pharmaceuticals Co., Ltd.
NSCLC (Non-small Cell Lung Cancer), Solid Tumor
A Phase 1/2, Open-label, Multicenter, FIH Study to Evaluate Safety, Tolerability, PK and Anti-tumor Activity of YH42946
The goal of this YH42946-101 is to evaluate the safety, Tolerability, Pharmacokinetics and anti-tumor activity of YH42946 in patients with locally advanced of metastatic solid tumors with HER2 aberration and EGFR exon 20…
- Trial name
- NCT06616766
- Testing
- YH42946
- Where
- 8 sites in United States, South Korea
- Volunteers
- 201 people
- Sponsor
- Yuhan Corporation
Carcinoma, Hepatocellular
A Dose-Finding and Exploratory Study of RO5323441 in Combination With Sorafenib in Patients With Hepatocellular Carcinoma
This open-label study will assess the safety, efficacy and pharmacokinetics of RO5323441 in combination with sorafenib in patients with advanced or metastatic hepatocellular carcinoma previously untreated with systemic therapy.
- Trial name
- NCT01308723
- Testing
- RO5323441, sorafenib
- Where
- 2 sites in Singapore
- Volunteers
- 6 people
- Sponsor
- Hoffmann-La Roche
Advanced Solid Tumors, Pancreatic Cancer
Phase 1/2 Study to Evaluate Safety, PK and Efficacy of the MYC-Inhibitor OMO-103 in Solid Tumours
This study is an open label, two-part, First in Human (FIH) Phase 1/2 dose-finding study designed to determine the safety, tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD) and proof-of-concept (POC) of OMO-103 in…
- Conditions
- Advanced Solid Tumors, Pancreatic Cancer, CRC
- Trial name
- MYCure (NCT04808362)
- Testing
- OMO-103
- Where
- 3 sites in Spain
- Volunteers
- 22 people
- Sponsor
- Peptomyc S.L.